Holen Sie sich die Stockscreener-App
27.47
0.94%
-0.26
Vorhandelsmarkt:
27.46
-0.010
-0.04%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt PFE?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$27.73
Offen:
$27.65
24-Stunden-Volumen:
55.45M
Relative Volume:
0.97
Marktkapitalisierung:
$156.19B
Einnahmen:
$62.58B
Nettoeinkommen (Verlust:
$7.79B
KGV:
20.27
EPS:
1.3551
Netto-Cashflow:
$10.38B
1W Leistung:
+3.70%
1M Leistung:
+8.71%
6M Leistung:
+11.44%
1J Leistung:
+7.85%
1-Tages-Spanne:
$27.41
$27.89
1-Wochen-Bereich:
$26.52
$27.94
52-Wochen-Spanne:
$20.91
$27.94
Pfizer Inc Stock (PFE) Company Profile
Firmenname
Pfizer Inc
Sektor
Telefon
(212) 733-2323
Adresse
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, AZN, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
27.47 | 157.66B | 62.58B | 7.79B | 10.38B | 1.3551 |
|
LLY
Lilly Eli Co
|
1,038.27 | 908.63B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
244.55 | 580.30B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
227.50 | 390.40B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
AZN
Astrazeneca Plc
|
204.52 | 317.44B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
161.18 | 305.42B | 54.72B | 14.02B | 15.32B | 7.1855 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-12 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-02 | Fortgesetzt | Citigroup | Neutral |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-11-15 | Eingeleitet | Wolfe Research | Underperform |
| 2024-10-25 | Fortgesetzt | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | Herabstufung | Argus | Buy → Hold |
| 2024-02-23 | Eingeleitet | Guggenheim | Buy |
| 2024-01-04 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-10-16 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-17 | Bestätigt | JP Morgan | Neutral |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-06-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | Herabstufung | UBS | Buy → Neutral |
| 2023-01-17 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-12-13 | Hochstufung | Goldman | Neutral → Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-01-05 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-20 | Bestätigt | Cowen | Outperform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-13 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-09 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-05-06 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | Hochstufung | DZ Bank | Hold → Buy |
| 2020-12-16 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | Fortgesetzt | Goldman | Neutral |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-10-12 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-16 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-27 | Hochstufung | Standpoint Research | Hold → Buy |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-07-30 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-02-20 | Fortgesetzt | Citigroup | Neutral |
| 2019-01-31 | Hochstufung | Argus | Hold → Buy |
| 2019-01-31 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | Herabstufung | UBS | Buy → Neutral |
| 2018-12-11 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-11-01 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
Alle ansehen
Pfizer Inc Aktie (PFE) Neueste Nachrichten
Pfizer Inc. $PFE Position Cut by CENTRAL TRUST Co - MarketBeat
Illinois Municipal Retirement Fund Cuts Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer (PFE) Sees Mixed Options Sentiment Amid Stock Downgrade - GuruFocus
Glioblastoma Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | InovioPharma, Pfizer, Roche, ACADIA Pharma, BioNTech, Oncotelic Therapeutics - Barchart.com
Varma Mutual Pension Insurance Co Purchases 82,500 Shares of Pfizer Inc. $PFE - MarketBeat
ING Groep NV Lowers Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by LSV Asset Management - MarketBeat
Pfizer (NYSE:PFE) Cut to Neutral at Daiwa Securities Group - MarketBeat
Here Are Thursday’s Top Wall Street Analyst Research Calls: BP Plc., Borg Warner, Generac, Kraft-Heinz, MercadoLibre, Pfizer, Shopify, Valvoline, and More - 24/7 Wall St.
Madison Asset Management LLC Has $6.17 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Shares Hit Annual Peak on Regulatory and Strategic Momentum - AD HOC NEWS
Analyst recommendations: Pfizer, Applovin, Biogen, Hilton, Snap… - marketscreener.com
Caprock Group LLC Makes New Investment in Pfizer Inc. $PFE - MarketBeat
Daiwa Securities Downgrades Pfizer to Neutral From Outperform, Price Target is $27 - marketscreener.com
Pfizer Hemophilia And Obesity Updates Reshape Growth And Valuation Outlook - Yahoo! Finance Canada
Pfizer, SEC Reach $29M Deal In Insider Trading Fund Dispute - Law360
Pfizer: A Great Opportunity Post Earnings (NYSE:PFE) - Seeking Alpha
Pfizer, SEC Reach $29M End to Scrap Over Insider Trading Settlement - Law.com
Pfizer Balances New Therapies And Pricing With Fresh Biotech Partnerships - simplywall.st
Is Now the Best Time to Buy Pfizer Stock? - The Globe and Mail
Pfizer Reports Strong Earnings OutlookUnusual Call Options Activity Shows Investors are Bullish - Yahoo Finance
Pfizer (PFE) Closes 2025 on Solid Note, Returns $9.8B to Shareholders - Finviz
Can Pfizer's New & Acquired Drugs Offset Its Looming Patent Cliff? - The Globe and Mail
Is Pfizer Stock Now A Value Trap? - Forbes
Wealthfront Advisers LLC Has $14.76 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Oppenheimer Asset Management Inc. - MarketBeat
Enzyme Inhibitors Market Is Going to Boom |• Pfizer • Merck & Co. - openPR.com
Is Pfizer Stock Heading for a Fall? - Trefis
Pfizer Inc. $PFE Shares Bought by Advisors Asset Management Inc. - MarketBeat
Can Pfizer Stock Withstand These Pressures? - Trefis
Pfizer Gets $29 Million of SAC Capital Insider Trade SEC Payout - Bloomberg Law News
Pfizer (NYSE:PFE) Shares Up 2.1%Still a Buy? - MarketBeat
Pfizer (NYSE:PFE) Sets New 1-Year HighStill a Buy? - MarketBeat
Pfizer stock hits 52-week high at 27.7 USD - Investing.com
Pfizer stock jumps as PFE taps a Swiss biotech incubator — here’s what Wall Street is watching next - Bez Kabli
Smart Money Is Betting Big In PFE Options - Benzinga
Pfizer Inc. (PFE) is a trending stock: Facts to know before betting on it - MSN
Pfizer Inc. (PFE) Announces FDA’s Grant of Priority Review for HYMPAVZI® (marstacimab) sBLA - Yahoo Finance
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Pfizer Becomes Newest Partner Added to BaseLaunch's Biotech Venture Incubator - PR Newswire
Pfizer Inc. (PFE) Announces FDA's Grant of Priority Review for HYMPAVZI (marstacimab) sBLA - Finviz
5 Revealing Analyst Questions From Pfizer’s Q4 Earnings Call - The Globe and Mail
Tetracyclines Market is Poised to Garner Valuation of USD 5.63 Billion by 2035 | Astute Analytica - GlobeNewswire Inc.
5 Revealing Analyst Questions From Pfizer's Q4 Earnings Call - Finviz
BridgePort Financial Solutions LLC Has $3.35 Million Holdings in Pfizer Inc. $PFE - MarketBeat
Stock Watch: Pfizer Navigates Vaccine Gains And Acquisition Pains - Citeline News & Insights
Pfizer shares gain 9% after Q3FY26 profit up 11%, revenue grows 20% - The Economic Times
Pfizer Balances TrumpRx Drug Discounts And HYMPAVZI Review With Valuation Gap - Yahoo Finance UK
Should You Buy Pfizer's Stock for Its 6.3%-Yielding Dividend? - Nasdaq
Pfizer (PFE) Tied to Drug Listings on Emerging TrumpRx Platform - GuruFocus
Freedom Capital Markets lowers Pfizer stock price target to $33 on COVID unwind - Investing.com
Finanzdaten der Pfizer Inc-Aktie (PFE)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.56%
0.39%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):